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Fatigue Is Associated With Quality of
Life in Sarcoidosis Patients*
Helen J. Michielsen, PhD; Marjolein Drent, MD, PhD;
Tatjana Peros-Golubicic, MD, PhD; and Jolanda De Vries, PhD, MSc
Background: Fatigue is one of the core symptoms of sarcoidosis patients. Although it is known that
fatigue affects quality of life (QOL) in other patient groups, this relationship has never been
studied in sarcoidosis patients using a reliable and valid fatigue scale and a multidimensional
QOL instrument. The present cross-sectional study among sarcoidosis patients attempts to gain
more insight into this relationship.
Methods: One hundred forty-five sarcoidosis patients of an outpatient pulmonary clinic in Zagreb,
Croatia, completed the Fatigue Assessment Scale (FAS) and QOL scale (World Health Organi-
zation Quality of Life Assessment Instrument-100) between January 2002 and May 2004. Clinical
parameters were derived from the patients’ medical files.
Results: Tired patients reported a worse QOL in all domains and fatigue negatively predicted all
QOL domains by means of multivariate regression analyses ( values ranging from  0.31 to
 0.64, all p < 0.001). Corticosteroid use was not a predictor of QOL. Diffusion capacity of the
lung for carbon monoxide was the only clinical parameter associated with a QOL domain, namely
level of independence.
Conclusions: Fatigue was related to all QOL domains. Furthermore, standard clinical parameters
were not associated with fatigue or QOL, except for level of independence. If these results were
to be replicated in a prospective study, fatigue as measured by the FAS could be a good indicator
of QOL in sarcoidosis patients. (CHEST 2006; 130:989–994)
Key words: fatigue; quality of life; sarcoidosis
Abbreviations: Dlco  diffusing capacity of the lung for carbon monoxide; FAS  Fatigue Assessment Scale;
QOL  quality of life; WHOQOL-100  World Health Organization Quality of Life Assessment Instrument-100
S arcoidosis is a multiorgan disorder of unknownorigin. In young adults, pulmonary sarcoidosis is
the second-most-common respiratory disease after
asthma. Its clinical manifestations are largely non-
specific, depending on the intensity of the inflamma-
tion and organ system.1 The disease is most fre-
quently situated in the lungs, but practically any
organ can be involved. Constitutional symptoms,
such as fever and weight loss, as well as chest-related
symptoms, such as coughing, dyspnea, and chest
discomfort, may be present. Fatigue is one of the
core symptoms in sarcoidosis patients.2–4 James5
described the “post-sarcoidosis chronic fatigue syn-
drome,” which entails the presence of fatigue in
patients with a history of sarcoidosis, even when the
chest radiograph and markers of disease activity have
returned to normal.
Besides fatigue, sarcoidosis patients had a worse
QOL, as measured by the World Health Organiza-
tion Quality of Life Assessment Instrument-100
(WHOQOL-100), on the domains physical health,
level of independence, and overall QOL in compar-
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ison with healthy control subjects.6 Medical factors,
such as pulmonary function3,7,8 or time since diag-
nosis,9 could not account for the suboptimal QOL.
Previous studies among patients with other diseases,
eg, multiple sclerosis,10 breast cancer,11 and the
chronic fatigue syndrome,12 found that subjectively
experienced fatigue affected health status. Till now,
the relationship between fatigue and QOL has never
been the object of study in sarcoidosis. An attempt
using a facet of the WHOQOL-100, energy and
fatigue, and the domain of psychological health was
performed by Wirnsberger et al,7 who reported a
nonsignificant relationship between these scales.
The aim of this study was to evaluate the relationship




The sample consisted of consecutive patients from Jordanovic
Hospital in Zagreb, Croatia, who were asked by their pulmonary
physician to complete a questionnaire. One hundred fifty patients
participated in this study. Complete spirometry and diffusion
capacity of the lung for carbon monoxide (Dlco) data were
available from 145 patients. Therefore, these 145 patients were
selected for all analyses. Fifty-two men (36%) and 93 women
(64%) had a mean age of 44.3 years (SD, 9.1; range, 21 to 75
years). Mean time since diagnosis was 4.0 years (SD, 7.8; range,
0 to 49 years). Diagnosis of sarcoidosis was based on consistent
clinical features, together with biopsy-proven noncaseating epi-
thelioid cell granulomas according to the international guide-
lines.1 The clinical symptoms of the patients varied from none
(sarcoidosis detected on routine chest radiography) to more or
less severe respiratory symptoms or symptoms related to other
organ involvement. Of all patients, 84.8% were living with a
partner. Furthermore, 19.3% had a low education level (primary
school), and 20.7% had a college education level. The procedures
followed were in accordance with the Helsinki declaration of
1975, as revised in 1983. The institutional internal review board
approved the study protocol, and written informed consent was
obtained from all patients.
Measures
All respondents completed the Fatigue Assessment Scale
(FAS)13 and the WHOQOL-100,14 Croatian version.15 Data
concerning clinical parameters were derived from medical files.
Lung Function Testing: Lung function measurements, includ-
ing FEV1 and FVC, were measured with a pneumotachograph.
Dlco was measured by the single-breath method (both Master-
lab; Jaeger; Wurzburg, Germany). Values were expressed as a
percentage of those predicted.
Chest Radiographs: Chest radiographs were graded according
to the radiographic staging of DeRemee (0 to III), adding stage
IV, the end stage of lung fibrosis. Two groups were distinguished:
one group included stages 0 and I, and the second group stages
II to IV.
Symptoms: A symptom inventory questionnaire consisted of 43
items including dichotomous questions concerning current symp-
toms, such as breathlessness, reduced exercise capacity, arthral-
gia, and fatigue. The questionnaire was used in several previous
studies.2,9
The FAS is a fatigue questionnaire consisting of 10 items: 5
questions reflecting physical fatigue, and 5 questions assessing
mental fatigue. Although these two aspects of fatigue are repre-
sented in the questionnaire, the FAS was unidimensional when
completed by a Dutch working population and a representative
group of the general population,13,16 as well as by two groups of
Dutch sarcoidosis patients8 and the present Croatian sample.17
The unidimensional structure points out that the proper score to
use here is the FAS total score. The response scale is a 5-point
scale (1  never, 5  always). Scores on the FAS range from 10
to 50. The psychometric properties are good in healthy13,16 and
sarcoidosis patients.8 The translation procedure of the FAS in the
Croatian language followed the translation-backtranslation pro-
cedure.18 The Croatian FAS has also shown good psychometric
properties in the Croatian sarcoidosis sample of the present
study.17
The WHOQOL-100 is a cross-culturally developed, generic,
multidimensional QOL that measures 100 items.14 The general
evaluative facet consists of 4 questions, and the other 96 ques-
tions assess 24 facets of QOL within six domains: physical health,
psychological health, level of independence, social relationships,
environment, and spirituality. Each facet is represented by four
items with a 5-point Likert-type response scale. Scores on each
facet and domain can range from 4 to 20. The reliability and
validity of this instrument, which have also been tested in groups
of Dutch individuals with sarcoidosis, are good.19,20 The psycho-
metric qualities of the WHOQOL-100 in a Croatian diabetic
group are adequate.15
Statistical Procedure
Frequencies were used to present the available demographic,
medical, and psychological data. Pearson correlations were cal-
culated between the FAS and the WHOQOL-100 domains and
facets. When fatigue was examined in relation to the QOL facet
energy and fatigue and the QOL domain physical health, the two
overlapping items (“Do you have enough energy for everyday
life” and “Are you bothered by fatigue”) were removed from the
FAS total score to avoid overlap. We also computed a correlation
between the FAS and the QOL domain physical health without
the QOL facet energy and fatigue, thereby removing four QOL
items. Following Cohen,21 absolute correlations between 0.10
and 0.29 are considered small, between 0.30 and 0.49 are
considered medium, and  0.50 as large. In addition, we divided
the total FAS score into two groups: FAS scores 10 to 21 (not
tired) and FAS scores 22 to 50 (tired). In line with De Vries et
al,22 we also divided the FAS into three groups, 10 to 21, 22 to 34,
and 35 to 50. The last group consists of individuals who are
extremely fatigued. We compared both FAS score divisions on
QOL domains and facets using multivariate analysis of variance.
When the results for the domains and facets were considered
separately, we used a Bonferroni-adjusted  level. Finally, seven
hierarchical regression analyses were performed with the six
WHOQOL domains and overall QOL as dependent variable. In
block 1, gender and age were included. Block 2 consisted of the
clinical parameters time since diagnosis, smoking behavior,
Dlco, FEV1, FVC, disease stage, and corticosteroid use. Block 3
contained the FAS. All p values were two tailed, and SPSS 11.5
(SPSS; Chicago, IL) was used to perform all statistical analysis.
Results
The demographic, medical, and psychological char-
acteristics are summarized in Table 1. The population
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consisted of a vast majority of women, and the mean
age was 44.33  9.91 years. Women had more fatigue
than men (t[1,133]   3.18, p  0.01; Table 2). Mean
time since diagnosis was 4.04  7.80 years, and nearly
half of the sample used corticosteroids. The patients
using corticosteroids were more tired than the patients
who did not (t[1,133]   3.50, p  0.01). Of the
patients who did not use corticosteroids at the time of
the study, two reported taking corticosteroids  1
month ago, one  6 months ago, and two from 6 to
12 months ago. Fatigue was the most common com-
plaint (n  85, 59.4%), followed by breathlessness
(n  67, 46.2%), reduced exercise capacity (n  65,
44.8%), and arthralgia (n  54, 37.2%). Tired individuals
Table 1—Demographic and Medical Characteristics of the Croatian Sarcoidosis Patients*





Male/female gender, No. 52/93 52 93 28/45 24/48
Age, yr 44.3  9.9 42.4  9.0 45.4  10.3† 46.0  9.8 42.6  9.8
With partner, No.
Yes 123 44 79 64 59
No 21 8 13 9 12
Missing 1 0 1 0 1
Education, No.
Low 28 3 25‡ 18 10
Middle 82 33 49‡ 43 39
High 30 14 16‡ 9 21
Missing 5 2 3‡ 3 2
Medical data
Time since diagnosis 4.0  7.8 (median, 1) 3.7  8.6 4.2  7.4 5.5  8.6 2.5  6.6†
Smoking status
Never 113 38 75 58 55
Stopped 21 8 12 10 10
 1 yr 12 6 6 5 7
Corticosteroid use
Yes 73 28 45 73 72
No 72 24 48
Lung function results, % predicted
Dlco 85.7  15.5 85.4  14.9 85.9  15.9 83.6  16.9 87.7  13.7
FEV1 96.7  20.6 93.0  21.5 98.8  19.9 93.2  21.5 100.3  19.1†
FVC 98.0  16.8 92.6  14.6 101.0  17.2‡ 95.6  18.6 100.4  14.4
Radiographic stage
0 23 6 17† 14 9†
I 47 12 35† 11 36†
II 46 26 20† 23 23†
III 28 8 20† 24 4†
IV 1 0 1† 1 0†
*Data are expressed as mean  SD unless otherwise indicated.
†p  0.05.
‡p  0.01.
Table 2—Fatigue and QOL in Croatian Sarcoidosis Patients*





FAS 24.2  8.1 21.3  8.3 25.8  7.5 26.5  8.3 21.8  7.2
Overall QOL 13.7  2.6 14.4  2.6 13.3  2.6† 13.2  2.8 14.2  2.3
Domain 1, physical health 13.3  3.1 14.7  3.1 12.5  2.9† 12.6  3.1 14.0  3.0†
Domain 2, psychological health 14.6  2.3 15.8  2.0 13.9  2.1† 13.9  2.5 15.2  1.9†
Domain 3, level of independence 14.1  3.4 14.9  3.5 13.6  3.3† 13.0  3.2 15.2  3.3†
Domain 4, social relationships 15.7  2.3 16.4  2.0 15.3  2.4† 15.3  2.5 16.0  2.1
Domain 5, environment 14.7  2.2 15.4  2.1 14.3  2.2† 14.3  2.4 15.1  2.0
Domain 6, spirituality 15.9  2.9 16.4  2.3 15.6  3.2† 15.2  2.8 16.6  2.8†
*Data are expressed as mean  SD.
†Significant at the Bonferroni-adjusted  level.
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reported less exercise capacity, more breathlessness,
and more arthralgia: t(1,131)   3.96, p  0.001;
t(1,129)   4.47, p  0.001; and t(1,131)   2.15,
p  0.05, respectively. Fatigue did not correlate  0.3
with Dlco, FEV1, or FVC (Table 3). Patients with
different radiographic stages did not differ according to
fatigue: t(1,133)   1.05 (p  0.05).
The WHOQOL facet energy and fatigue was strongly
related to fatigue after controlling for overlap in similar
items of both scales (r   0.76, p  0.001). High corre-
lations (r  0.50) were found between fatigue and the
QOL domains physical (r   0.73) and psychological
health (r   0.72, r   0.56, with physical health after
controlling for four-item overlap), level of independence
(r   0.71), and environment (r   0.51). At facet
level, fatigue was strongly associated with overall QOL
(r   0.58); pain and discomfort (r  0.52); positive
feelings (r  –0.57); cognitive functions (r   0.67);
self-esteem (r  – 0.58); negative feelings (r  0.60); mo-
bility (r   0.59); activities of daily living (r  – 0.77);
working capacity (r   0.65); personal relationships
(r   0.50); and physical safety and security
(r   0.52). Fatigue correlated  0.45 (all p  0.001)
with the facet sleep and rest.
A majority of 83 patients (57.3%) had a FAS score
 22 (tired). Twenty-one patients (14.5%) reported
a FAS score  35 (extremely tired). When the
high-fatigue and low-fatigue groups were compared
on QOL, tired patients had a worse QOL:
F(7,125)  13.72, p  0.000; and F(14,250)  6.85,
p  0.000 (Fig 1). For both FAS score group divi-
sions, tired patients differed from their energetic
counterparts in all domains. Tired patients also
reported a lower QOL on all facets compared with
the nonfatigued patients, with one exception. The
patients did not differ on the facet transport.
Finally, regression analyses showed that fatigue (
values ranging from  0.31 to  0.64, all p  0.001)
was the most important negative predictor of each
QOL domain after controlling for demographic and
clinical parameters (Table 4). Gender, age, time
since diagnosis, and Dlco in various combinations
were also predictors of QOL (total R2, 22 to 58%).
Corticosteroid use was not associated with QOL.
Discussion
Although fatigue is one of the major symptoms in
sarcoidosis and is known to affect different aspects of
QOL, the association between these two important
concepts has never been the main object of study in
sarcoidosis patients. Using psychometrically sound
questionnaires, the current cross-sectional study was
the first to scrutinize this relationship thoroughly.
Fatigue appeared to be strongly related to all aspects
of QOL, independently of other frequently reported
symptoms, clinical parameters, and demographics.
Standard clinical parameters of respiratory capacity
were only associated with level of independence. In
line with other studies,3,7,8 fatigue was not related to
respiratory functional impairment. Therefore, other
factors should be considered to account for this
devastating problem in sarcoidosis.
The association between fatigue and the QOL
domains physical and psychological health as well as
level of independence was very strong. Regarding
the physical health facets, the rather low association
between fatigue and the WHOQOL facet sleep and
rest points out that sleeping problems certainly are
not the only determinant of the subjective feeling of
fatigue. The high correlation between fatigue and
the level of independence domain supports the idea
that fatigue affects daily life. Fatigue seems to be a
debilitating symptom, affecting one’s possibilities to
live a self-governed live. In accordance with
Schweitzer et al,12 fatigue was a predictor of less
satisfaction with social relationships, although the
amount of variance was not high. The study of
Schweitzer did not concern patients with chronic
fatigue syndrome. Similar to sarcoidosis patients,
their main complaint is fatigue. Chronic fatigue
syndrome patients reported a reduced social support
network and less participation in social activities.
Surprisingly, items concerning physical safety influ-
Table 3—Correlations Among Fatigue, QOL, and
Clinical Parameters
Variables Dlco FEV1 FVC
FAS  0.18*  0.19*  0.18*
Overall QOL 0.02 0.04  0.01
Domain 1, physical health 0.25* 0.14 0.11
Domain 2, psychological health 0.16* 0.11 0.06
Domain 3, level of independence 0.26* 0.19* 0.15
Domain 4, social relationships 0.05 0.02  0.03
Domain 5, environment  0.05  0.01  0.08
Domain 6, spirituality 0.23* 0.12 0.13
*p  0.05.
Figure 1. Distribution of low, middle, and high scores on the
FAS.
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enced the relationship between the environment
domain and fatigue. The war in Croatia did not
influence the prevalence of sarcoidosis23 or the level
of psychosomatic complaints among civilians.24
Speculatively, it might be that these somatic patients
pay more attention to or are more sensitive to
environmental hazards because their health already
is affected. Finally, in line with a study using the
Sickness Impact Profile,3 fatigue was also strongly
related to overall QOL.
An obvious limitation of this study is its cross-
sectional nature. We cannot draw causal relationships
between fatigue and QOL.25 Secondly, although the
Croatian version of the WHOQOL-100 has not been
validated in a sarcoidosis sample, this language version
was developed as part of the original World Health
Organization QOL project, together with versions
developed in 14 other cultural settings.26 Because
overall psychometric properties of the WHOQOL-100
were good and the psychometric properties of the
WHOQOL-100 in a Croatian diabetic group were
adequate,15 we believe we have reliable QOL data. In
addition, because we merely used questionnaires, this
could have biased our results.27
However, until there is a “gold standard” for
measuring fatigue objectively, we can only measure
fatigue on a subjective level. It is well known that a
complex construct such as fatigue can be measured
more reliably when it is measured by more than one
item. Because fatigue is one symptom, if not the core
symptom, in sarcoidosis patients, its assessment
should be done thoroughly. The FAS has proven
good reliability and validity in sarcoidosis patients8,17;
therefore, the FAS can measure fatigue more ade-
quately than a fatigue item or a fatigue subscale of a
more global scale. Furthermore, the FAS is trans-
lated into several languages and is available from the
first author. It is a short, easy-to-administer scale;
because of this, we advise using the FAS in the
follow-up and management of sarcoidosis patients.
Besides the fact that fatigue is a major clinically
relevant problem in sarcoidosis, the present study
showed that it is strongly associated with various
domains of QOL. Moreover, in line with others,3,7,8
this study underlines the fact that regularly used
measurements such as spirometry are not appropri-
ate to depict the real impact of the disease on the
patients’ lives. Even if other measures of disease are
normal, fatigue might be a major problem for the
patient. Hence, treatment of sarcoidosis patients
should not only concentrate on improving clinical
parameters, but also pay attention to the subjective
experience of fatigue because of its debilitating
effect. Intervention studies, for instance cognitive
behavior therapy,28,29 are needed to investigate the
possibilities for improving energy levels and thereby
QOL. Future prospective studies could also focus on
the specific types of fatigue in sarcoidosis patients30
and their relationship with general QOL instruments
and sarcoidosis-specific scales.31 We would like to
stress the importance of including fatigue measure-
ment in the clinical follow-up of sarcoidosis patients.
Searching for the antecedents of fatigue in this
patient population in order to reduce fatigue and to
improve their QOL is mandatory.
Table 4—Demographic, Medical Factors, and Fatigue Predictors of QOL*
Variables B SE B  R2 R2
Overall QOL
Time since diagnosis  0.05 0.03  0.16†
Fatigue  0.19 0.03  0.59§ 0.39 0.26
Physical health revised
Being female  1.35 0.54  0.20†
Age  0.07 0.03  0.20†
Time since diagnosis 0.08 0.03 0.19†
Fatigue  0.20 0.03  0.49§ 0.43 0.19
Psychological health
Being female  0.96 0.34  0.20‡
Fatigue  0.18 0.02  0.64§ 0.58 0.31
Level of independence
Dlco 0.04 0.02 0.16†
Fatigue  0.27 0.03  0.64§ 0.58 0.31
Social relationships, fatigue  0.12 0.03  0.43§ 0.25 0.14
Environment, fatigue  0.14 0.02  0.50§ 0.31 0.19
Spirituality, fatigue  0.10 0.03  0.31‡ 0.22 0.07
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Appendix
FAS
The following 10 statements refer to how you usually feel. For
each statement, you can choose one of five answer categories
varying from never to always (1  never; 2  sometimes;
3  regularly; 4  often, and 5  always):
1. I am bothered by fatigue.
2. I get tired very quickly.
3. I don’t do much during the day.
4. I have enough energy for everyday life.
5. Physically, I feel exhausted.
6. I have problems getting started.
7. I have problems thinking clearly.
8. I feel no desire to do anything.
9. Mentally, I feel exhausted.
10. When I am doing something, I can concentrate quite well.
Items 4 and 10 require reversed scoring. The scale score is
calculated by summing all items.
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